Previous 10 | Next 10 |
2023-05-10 19:23:08 ET Matinas BioPharma Holdings, Inc. (MTNB) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Terry Matkovits – Chief De...
2023-05-10 16:49:30 ET Matinas Biopharma press release ( NYSE: MTNB ): Q1 GAAP EPS of -$0.03 in-line. Revenue of $1.1M beats by $0.8M . Cash, cash equivalents and marketable securities as of March 31, 2023 were $24.9 million compared with $28.8 million as of Decemb...
FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design is being finalized to support a broad label for IFIs under a 505(b)(2) regulator...
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, ann...
--News Direct-- Matinas BioPharma CEO & Co-founder Jerry Jabbour joins Natalie Stoberman from the Proactive newsroom to discuss the company's latest growth and momentum surrounding its MAT2203 trial as a potential oral broad-spectrum treatment for invasive deadly fungal infections. ...
2023-04-19 13:19:34 ET Matinas BioPharma ( NYSE: MTNB ) gained ~25% on Wednesday as the shares of the clinical-stage biotech continued to rally following limited but impactful data for its antimicrobial therapy MAT2203 targeted at patients with rare fungal infection R. mucilag...
BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Marisa H. Miceli, MD, Professo...
2023-03-15 20:26:17 ET Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Conference Call March 16, 2023 16:30 ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry ...
2023-03-15 16:19:10 ET Matinas Biopharma press release ( NYSE: MTNB ): FY GAAP EPS of -$0.10 beats by $0.01 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $28.8 million compared with $49.6 million as of December 31, 2021. Based on curre...
Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected to impact partnership discussions and facilitate potential non-dilutive BARDA and/or NIH f...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...